ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Sanofi Sells Dermik Unit To Valeant For $425 Million

PARIS -(Dow Jones)- French pharmaceutical giant Sanofi SA (SAN.FR) said Monday it sold Dermik, its dermatology unit, to Canada-based Valeant Pharmaceuticals International Inc. (VRX) for $425 million in cash. The transaction involves Dermik assets, comprising an aesthetic and therapeutic dermatology business in the U.S. and Canada and an aesthetic dermatology business in other parts of the world, which had sales of $206 million in 2010, Sanofi said. Dermik has a significant presence in the medical dermatology market in the U.S. and Canada, with a strong field force and well-known brands, which include BenzaClin, Carac and Sculptra. Sanofi decided to sell Dermik to focus on its "growth platforms" and "innovation." The French company recently bought U.S. biotech firm Genzyme for $20 billion and a string of smaller firms prior to the Genzyme takeover. The transaction will still have to be cleared by certain antitrust authorities and meet other customary conditions. -By Inti Landauro, Dow Jones Newswires; +33 1 4017 1740; [email protected]

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
02/21/201707:30:00Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement...
02/21/201707:30:00Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement...
02/16/201708:29:00AstraZeneca to Get $130 Million Payment as Psoriasis Drug Siliq...
02/16/201707:00:00Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe P...
02/16/201707:00:00Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe P...
02/14/201717:59:34Statement of Ownership (sc 13g)
02/13/201717:00:00Valeant Pharmaceuticals To Participate At Healthcare Conferences
02/13/201717:00:00Valeant Pharmaceuticals To Participate At Healthcare Conferences
02/13/201716:36:52Amended Statement of Beneficial Ownership (sc 13d/a)
02/13/201716:34:45Current Report Filing (8-k)
02/07/201712:25:01Amended Statement of Ownership (sc 13g/a)
01/30/201716:30:00Valeant To Hold Conference Call To Present Fourth Quarter And...
01/30/201716:30:00Valeant To Hold Conference Call To Present Fourth Quarter And...
01/17/201718:19:00Allergan Admits to Disclosure Violations During Valeant Bid
01/11/201703:03:00Valeant Sheds Assets to Pay Down Debt -- WSJ
01/11/201703:03:00L'Oréal Expands Its Strategy -- WSJ
01/10/201717:11:00Current Report Filing (8-k)
01/10/201716:13:52Current Report Filing (8-k)
01/10/201714:31:00Valeant to Sell Skin-Care Brands to L'Oreal -- 2nd Update
01/10/201709:13:00L'Oréal Looks to Gain U.S. Share by Buying Valeant Brands...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US